experimental group:Preoperative anrotenib hydrochloride combined with neoadjuvant chemotherapy

2 trials

Sponsors

Tumor Hospital Affiliated to Guangxi Medical University, Department of Otolaryngology, Mianyang Central Hospital, Sichuan Province

Conditions

Head and neck squamous cell carcinomaStage III-IVA resectable squamous cell carcinoma of the head and neck

Early Phase 1

A single-arm, single-center, phase II exploratory clinical study on the new preoperative adjuvant treatment of head and neck squamous cell carcinoma with combination of androtinib hydrochloride and DF

Active, not recruitingChiCTR2000030727

Tumor Hospital Affiliated to Guangxi Medical UniversityHead and neck squamous cell carcinoma

Start: 2020-06-01Updated: 2020-03-16

Phase 2

Anrotinib hydrochloride combined with TP in a single-arm, single-center, phase II exploratory clinical study in patients with stage III-IVA resectable squamous cell carcinoma of the head and neck

RecruitingChiCTR2100046440

Department of Otolaryngology, Mianyang Central Hospital, Sichuan ProvinceStage III-IVA resectable squamous cell carcinoma of the head and neck

Start: 2021-05-16Updated: 2022-01-04